PC
PCVX.US Vaxcyte Inc
- Market cap
- USD 10.0B
- P/E
- -
- P/B
- 4.03x
- ROE
- -48.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PCVX.US undervalued?
Graham numberThe Graham number of Vaxcyte Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vaxcyte Inc fundamental analysis
No fundamental analysis for Vaxcyte Inc yet.
Vaxcyte Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; …
Full company profileVaxcyte Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vaxcyte Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -1.04M | -1.23M | -1.41M | -1.80M | -9.20M | -75.0M | -15.8M | - | - |
| Operating Income | -17.8M | -35.5M | -54.2M | -89.6M | -104M | -232M | -468M | -570M | -924M | -1.28B |
| EBITDA | -17.2M | -28.4M | -49.0M | -87.8M | -96.6M | -214M | -392M | -448M | -742M | -1.19B |
| Net Income | -17.2M | -29.5M | -50.3M | -89.2M | -100M | -223M | -402M | -464M | -767M | -1.20B |
| EPS | -4.83 | -1.15 | -1.03 | -3.02 | -1.93 | -3.44 | -4.14 | -3.80 | -5.63 | -8.08 |
| Balance Sheet | ||||||||||
| Total Assets | 39.6M | 70.8M | 65.7M | 393M | 324M | 1.01B | 1.41B | 3.51B | 3.00B | 2.99B |
| Total Liabilities | 8.69M | 129M | 172M | 47.0M | 40.3M | 52.6M | 167M | 205M | 317M | 500M |
| Shareholders' Equity | 30.9M | -57.7M | -106M | 346M | 284M | 954M | 1.24B | 3.31B | 2.69B | 2.49B |
| Cash & Short-term Investments | 36.1M | 66.1M | 59.0M | 386M | 246M | 931M | 1.08B | 1.75B | 1.56B | 1.29B |
| Total Debt | 4.50M | 3.94M | 611K | - | 16.8M | 17.9M | 29.2M | 71.1M | 117M | 222M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -15.0K | -30.5M | -47.1M | -46.6M | -121M | -171M | -297M | -453M | -656M | -1.36B |
| Capital Expenditure | 1.22K | 1.77M | 1.20M | 1.16M | 6.56M | 5.84M | 67.9M | 22.4M | 13.7M | 52.2M |
| Free Cash Flow | -16.2K | -32.2M | -48.3M | -47.8M | -128M | -176M | -365M | -475M | -669M | -1.41B |
| Ratios | ||||||||||
| ROE | -55.7% | - | - | -25.8% | -35.2% | -23.4% | -32.4% | -14.0% | -28.5% | -48.3% |
| ROA | -43.5% | -41.6% | -76.5% | -22.7% | -30.9% | -22.2% | -28.6% | -13.2% | -25.5% | -40.2% |
| Debt to Equity | 0.15x | - | - | - | 0.06x | 0.02x | 0.02x | 0.02x | 0.04x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vaxcyte Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 374K | 0.01 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Vaxcyte Inc
- Insiders 0.74%
- Institutions 99.26%
- Public & others 0.00%
- Shares outstanding 158M
- Free float 146M
Top funds holding PCVX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation | 5.61M | 3.57% | +35.79% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.77M | 3.03% | +3.68% | Sep 2026 |
| iShares Russell 2000 ETF | 3.51M | 2.23% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 3.35M | 2.13% | +0.80% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 3.31M | 2.10% | +5.06% | Sep 2026 |
| Vanguard Health Care Inv | 3.01M | 1.91% | +12.97% | Sep 2026 |
| Janus Henderson Forty S | 2.68M | 1.70% | 0.00% | Sep 2026 |
| Janus Henderson Enterprise D | 2.27M | 1.44% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.14M | 1.36% | +2.68% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.86M | 1.18% | -2.40% | Sep 2026 |
| Fidelity Advisor Growth Opps M | 1.48M | 0.94% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.44M | 0.92% | +0.15% | Aug 2026 |
| T. Rowe Price Mid-Cap Growth | 1.30M | 0.83% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 1.28M | 0.81% | 0.00% | Aug 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 1.27M | 0.81% | +37.36% | Sep 2026 |
| Vanguard Explorer Inv | 1.27M | 0.80% | -3.96% | Sep 2026 |
| iShares Biotechnology ETF | 1.13M | 0.72% | -0.35% | Oct 2026 |
| T. Rowe Price Capital Apprec Eq ETF | 1.05M | 0.67% | -0.56% | Oct 2026 |
| Fidelity Select Biotechnology | 980K | 0.62% | 0.00% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 955K | 0.61% | +0.59% | Sep 2026 |
Top institutions holding PCVX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 20.9M | 13.25% | +26.44% | Jun 2026 |
| Jupiter Topco LLC | 18.0M | 11.41% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 12.2M | 7.76% | +0.67% | Jun 2026 |
| BlackRock Inc | 12.1M | 7.67% | +9.99% | Jun 2026 |
| RA Capital Management, LLC | 11.5M | 7.29% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 7.00M | 4.45% | +24.70% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.59M | 4.19% | +5.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.35M | 4.03% | +1.31% | Jun 2026 |
| State Street Corp | 5.35M | 3.40% | +20.52% | Jun 2026 |
| Deep Track Capital, LP | 4.30M | 2.73% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 3.46M | 2.20% | +8.06% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 3.28M | 2.08% | +32.64% | Sep 2026 |
| T. Rowe Price Associates, Inc. | 2.99M | 1.90% | +206.12% | Jun 2026 |
| Kynam Capital Management, LP | 2.92M | 1.86% | 0.00% | Jun 2026 |
| Caligan Partners LP | 2.19M | 1.39% | +6.21% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 2.13M | 1.35% | -55.61% | Jun 2026 |
| Bellevue Group AG | 1.97M | 1.25% | +65.61% | Jun 2026 |
| D. E. Shaw & Co LP | 1.90M | 1.21% | -33.62% | Jun 2026 |
| Maverick Capital Ltd | 1.61M | 1.03% | +17.09% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.46M | 0.93% | +4.34% | Jun 2026 |
Vaxcyte Inc company profile
- Company name
- Vaxcyte Inc
- Ticker
- PCVX.US
- Exchange
- USA Stocks
- Listed since
- Jun 12, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 507
- Fiscal year end
- December
- Address
- 825 Industrial Road, San Carlos, CA, United States, 94070
- Phone
- 650 837 0111
- Website
- vaxcyte.com
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte Inc management
10- Mr. Grant E. Pickering M.B.A.Co-Founder, CEO & Director · born 1968
- Mr. Andrew L. Guggenhime M.B.A.President & CFO · born 1968
- Mr. James T. Wassil M.B.A., M.S.Executive VP, Chief Scientific Officer & COO · born 1969
- Mr. Harpreet S. Dhaliwal M.B.A.Chief Technical Operations Officer · born 1973
- Dr. Jeff Fairman Ph.D.Co-Founder & VP of Research · born 1964
- Ms. Elvia CowanSenior VP of Finance & Chief Accounting Officer · born 1973
- Mr. Jeff MacdonaldExecutive Director of Investor Relations
- Mr. David McAvoy J.D.Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
- Ms. Whitney JonesChief People Officer
- Ms. Janet GraesserSenior Vice President of Corporate Affairs